News

Treatment with Kalydeco (ivacaftor) reduces the number of Pseudomonas aeruginosa bacteria in the lungs during an acute infection, but not during a chronic infection, a study using a rat model of cystic fibrosis (CF) indicates. Kalydeco led to better outcomes, including weight gain, increased CFTR protein function, and…

Children and adolescents with cystic fibrosis (CF) interviewed for a study expressed a desire for active participation in the hospital setting and during CT scans, and wanted greater involvement during longer, more painful procedures. “It’s a fair right to have, after all, [children and adolescents are] the ones [it]…

Researchers discovered a molecule that may help deliver gene therapies to cells in the thick mucus environment of the cystic fibrosis (CF) lung, a study reported. Since thick mucus makes gene delivery to the CF lung a significant challenge, “we are encouraged by these results and anticipate that our…

Since its approval in 2019, treatment with Trikafta has markedly reduced the number of lung transplants among people in the U.S. with cystic fibrosis (CF), with more than 35 patients removed from a transplant waitlist the year after the therapy was approved, according to a new analysis. Moreover,…

Infection with an airway bacterium called Haemophilus influenzae isn’t linked with worse lung health outcomes among adults with cystic fibrosis (CF), a study suggests. “Our study is the first to specifically dissect the natural history and consequences of H. influenzae infection in adult [people with] CF,” the researchers wrote. The…

People with cystic fibrosis-related diabetes (CFRD) have lower pancreatic production of the GLP-1 receptor (GLP-1R), a protein that binds the hormone GLP-1 and triggers insulin secretion, a study reported. “Signaling of GLP-1 (and its ability to enhance insulin secretion) may be impaired as a result of reduced GLP-1R availability,”…

A young man with cystic fibrosis (CF) successfully underwent a heart transplant, according to a first-of-its kind report described by researchers, who said the man’s heart issues arose as a rare complication of CF itself. The patient’s experience was described in the paper, “Isolated heart transplantation…

The Cystic Fibrosis Foundation is investing up to $15 million in Recode Therapeutics to help spur the development of new gene-editing medicines for people with cystic fibrosis (CF) who don’t have effective treatment options. “We are grateful to the CF Foundation for their ongoing support of our…

A Phase 1/2 clinical trial testing the inhaled gene therapy SP-101 in adults with cystic fibrosis (CF) has begun dosing, and is still recruiting participants, according to its developer Spirovant Sciences. The trial, called SAAVe (NCT06526923), aims to enroll 15 CF patients, ages 18 to 65. To…

Rostra Therapeutics has launched a research project with the support of funding from the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate that seeks to identify new small molecules that can destroy fungi or stop them from growing and causing infections in people with cystic fibrosis (CF). Rostra…